Education
About Us
Working with TipRanks
Follow Us
Achieve Life Sciences (ACHV)
:ACHV
ACHV Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ACHV Stock 12 Month Forecast
Average Price Target
$14.60
▲(208.02% Upside)
| Highest Price Target$20.00 | Average Price Target$14.60 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$12
Buy
153.16%
Upside
Reiterated
11/06/25
Achieve Life Sciences: Advancements in Cytisinicline Propel Buy Rating Amid Regulatory Milestones and Clinical SuccessWe base our valuation on our discounted cash flow. We use a 10.9% weighted average cost of capital (WACC), and a 12.5x exit multiple on our 2031 estimates. We assume a 2026 approval and launch of cytisinicline in the U.S. for smoking, and assign a 75% probability of success. For vaping cessation we assign a 60% probability of success, and a 2028 launch. Risks to our thesis include: 1) Commercial execution risk, 2) Clinical trial risk, 3) Regulatory risk, 4) Financing risk, and 5) Risk that a partner may be required, and if so this partner could control commercialization efforts.
Lake Street
$11
Buy
132.07%
Upside
Reiterated
11/03/25
JonesTrading
$20
Buy
321.94%
Upside
Reiterated
10/17/25
Raymond James
$20
Buy
321.94%
Upside
Reiterated
10/17/25
Maxim Group
$10
Buy
110.97%
Upside
Reiterated
09/03/25
LifeSci Capital
$11
Buy
132.07%
Upside
Reiterated
01/08/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$12
Buy
153.16%
Upside
Reiterated
11/06/25
Achieve Life Sciences: Advancements in Cytisinicline Propel Buy Rating Amid Regulatory Milestones and Clinical SuccessWe base our valuation on our discounted cash flow. We use a 10.9% weighted average cost of capital (WACC), and a 12.5x exit multiple on our 2031 estimates. We assume a 2026 approval and launch of cytisinicline in the U.S. for smoking, and assign a 75% probability of success. For vaping cessation we assign a 60% probability of success, and a 2028 launch. Risks to our thesis include: 1) Commercial execution risk, 2) Clinical trial risk, 3) Regulatory risk, 4) Financing risk, and 5) Risk that a partner may be required, and if so this partner could control commercialization efforts.
Lake Street
$11
Buy
132.07%
Upside
Reiterated
11/03/25
JonesTrading
$20
Buy
321.94%
Upside
Reiterated
10/17/25
Raymond James
$20
Buy
321.94%
Upside
Reiterated
10/17/25
Maxim Group
$10
Buy
110.97%
Upside
Reiterated
09/03/25
LifeSci Capital
$11
Buy
132.07%
Upside
Reiterated
01/08/25
Best Analysts Covering Achieve Life Sciences
1 Month
xxx
Success Rate
7/13 ratings generated profit
Average Return
+13.05%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +13.05% per trade.
3 Months
xxx
Success Rate
13/21 ratings generated profit
Average Return
+4.13%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +4.13% per trade.
1 Year
Success Rate
9/13 ratings generated profit
Average Return
+9.77%
reiterated a buy rating 10 months ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +9.77% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
Average Return
+46.07%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +46.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ACHV Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
7
5
11
14
13
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
5
11
14
13
Each month's total comprises the sum of three months' worth of ratings.
ACHV Financial Forecast
ACHV Stock Forecast FAQ
What is ACHV’s average 12-month price target, according to analysts?
Based on analyst ratings, Achieve Life Sciences’s 12-month average price target is 14.60.
What is ACHV’s upside potential, based on the analysts’ average price target?
Achieve Life Sciences has 208.02% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACHV a Buy, Sell or Hold?
Achieve Life Sciences has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Achieve Life Sciences’s price target?
The average price target for Achieve Life Sciences is 14.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 208.02% Increase from the current price of $4.74.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 208.02% Increase from the current price of $4.74.
What do analysts say about Achieve Life Sciences?
Achieve Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of ACHV?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.